Kathryn H. Brown

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul et al. · Clinical Cancer Research · 2010 · 210 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

Kathryn H. Brown, Craig Comisar, Han Witjes et al. · British Journal of Clinical Pharmacology · 2016 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

David Planchard, Kathryn H. Brown, Dong‐Wan Kim et al. · Cancer Chemotherapy and Pharmacology · 2016 · 144 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +12

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

Elizabeth Fox, Richard Aplenc, Rochelle Bagatell et al. · Journal of Clinical Oncology · 2010 · 108 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17